These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 19420010

  • 1. Alfacalcidol prevents aromatase inhibitor (Letrozole)-induced bone mineral loss in young growing female rats.
    Mohamed I, Yeh JK.
    J Endocrinol; 2009 Aug; 202(2):317-25. PubMed ID: 19420010
    [Abstract] [Full Text] [Related]

  • 2. Effects of aromatase inhibitors letrozole and anastrazole on bone metabolism and steroid hormone levels in intact female rats.
    Kumru S, Yildiz AA, Yilmaz B, Sandal S, Gurates B.
    Gynecol Endocrinol; 2007 Oct; 23(10):556-61. PubMed ID: 17952760
    [Abstract] [Full Text] [Related]

  • 3. Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys.
    Wickman S, Kajantie E, Dunkel L.
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3785-93. PubMed ID: 12915670
    [Abstract] [Full Text] [Related]

  • 4. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
    Gasser JA, Green JR, Shen V, Ingold P, Rebmann A, Bhatnagar AS, Evans DB.
    Bone; 2006 Oct; 39(4):787-95. PubMed ID: 16844441
    [Abstract] [Full Text] [Related]

  • 5. Greater efficacy of alfacalcidol in the red than in the yellow marrow skeletal sites in adult female rats.
    Tian XY, Liu XQ, Chen HY, Setterberg RB, Li M, Jee WS.
    J Musculoskelet Neuronal Interact; 2008 Oct; 8(3):257-66. PubMed ID: 18799859
    [Abstract] [Full Text] [Related]

  • 6. Alfacalcidol prevents age-related bone loss and causes an atypical pattern of bone formation in aged male rats.
    Li M, Healy DR, Li Y, Simmons HA, Su M, Jee WS, Shen VW, Thompson DD.
    J Musculoskelet Neuronal Interact; 2004 Mar; 4(1):22-32. PubMed ID: 15615075
    [Abstract] [Full Text] [Related]

  • 7. Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats.
    Vanderschueren D, van Herck E, Nijs J, Ederveen AG, De Coster R, Bouillon R.
    Endocrinology; 1997 Jun; 138(6):2301-7. PubMed ID: 9165015
    [Abstract] [Full Text] [Related]

  • 8. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA, Z-FAST and ZO-FAST Study Groups.
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [Abstract] [Full Text] [Related]

  • 9. Alfacalcidol-stimulated focal bone formation on the cancellous surface and increased bone formation on the periosteal surface of the lumbar vertebrae of adult female rats.
    Chen H, Tian X, Liu X, Setterberg RB, Li M, Jee WS.
    Calcif Tissue Int; 2008 Feb; 82(2):127-36. PubMed ID: 18175034
    [Abstract] [Full Text] [Related]

  • 10. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats.
    Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KP.
    Clin Cancer Res; 2004 Sep 01; 10(17):5717-23. PubMed ID: 15355898
    [Abstract] [Full Text] [Related]

  • 11. Effects of alfacalcidol on mechanical properties and collagen cross-links of the femoral diaphysis in glucocorticoid-treated rats.
    Saito M, Marumo K, Ushiku C, Kato S, Sakai S, Hayakawa N, Mihara M, Shiraishi A.
    Calcif Tissue Int; 2011 Apr 01; 88(4):314-24. PubMed ID: 21327766
    [Abstract] [Full Text] [Related]

  • 12. A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis.
    Shiraishi A, Higashi S, Masaki T, Saito M, Ito M, Ikeda S, Nakamura T.
    Calcif Tissue Int; 2002 Jul 01; 71(1):69-79. PubMed ID: 12073154
    [Abstract] [Full Text] [Related]

  • 13. Effects of alfacalcidol on cancellous and cortical bone mass in rats treated with glucocorticoid: a bone histomorphometry study.
    Iwamoto J, Seki A, Takeda T, Yamada H, Sato Y, Yeh JK.
    J Nutr Sci Vitaminol (Tokyo); 2007 Jun 01; 53(3):191-7. PubMed ID: 17874822
    [Abstract] [Full Text] [Related]

  • 14. [Effects of alfacalcidol on osteoporosis in ovariectomized rats].
    Xia W, Meng X, Xing X.
    Zhonghua Yi Xue Za Zhi; 2000 Sep 01; 80(9):702-5. PubMed ID: 11798840
    [Abstract] [Full Text] [Related]

  • 15. Effects of letrozole on hippocampal and cortical catecholaminergic neurotransmitter levels, neural cell adhesion molecule expression and spatial learning and memory in female rats.
    Aydin M, Yilmaz B, Alcin E, Nedzvetsky VS, Sahin Z, Tuzcu M.
    Neuroscience; 2008 Jan 02; 151(1):186-94. PubMed ID: 18061360
    [Abstract] [Full Text] [Related]

  • 16. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
    Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P.
    Clin Breast Cancer; 2012 Feb 02; 12(1):40-8. PubMed ID: 22014381
    [Abstract] [Full Text] [Related]

  • 17. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.
    J Clin Oncol; 2006 Aug 01; 24(22):3629-35. PubMed ID: 16822845
    [Abstract] [Full Text] [Related]

  • 18. Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats.
    Tanaka Y, Nakamura T, Nishida S, Suzuki K, Takeda S, Sato K, Nishii Y.
    J Bone Miner Res; 1996 Mar 01; 11(3):325-36. PubMed ID: 8852943
    [Abstract] [Full Text] [Related]

  • 19. TEI-3313, a novel prostaglandin A1 derivative, prevents bone loss and enhances bone formation in immobilized male rats.
    Ohta T, Azuma Y, Kanatani H, Kiyoki M, Koshihara Y.
    J Pharmacol Exp Ther; 1995 Oct 01; 275(1):450-5. PubMed ID: 7562584
    [Abstract] [Full Text] [Related]

  • 20. Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
    Uyar Y, Baytur Y, Inceboz U, Demir BC, Gumuser G, Ozbilgin K.
    Maturitas; 2009 Jul 20; 63(3):261-7. PubMed ID: 19386450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.